OrbiMed Genesis GP LLC (CIK 1808744) reported 55 SEC Form 4 insider transactions across 11 companies over the past 18 months (most recent 2026-06-24). Recent activity: Sell ELVN (24,846 shares), Sell ELVN (1,477 shares), Sell ELVN (787,024 shares), Sell ELVN (46,776 shares), Sell ELVN (9,086 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | Insider | Sell | 24,846 | $1.1M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | Insider | Sell | 1,477 | $66,465 |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | Insider | Sell | 787,024 | $35.7M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | Insider | Sell | 46,776 | $2.1M |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | Insider | Sell | 9,086 | $409,052 |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | Insider | Sell | 272,322 | $12.3M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 625,000 | $5.0M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 1.2M | $10.0M |
| 2026-04-23 | Prelude Therapeutics Inc (PRLD) | Director | Buy | 1.7M | $7.5M |
| 2026-04-23 | Prelude Therapeutics Inc (PRLD) | Director | Buy | 1.1M | $5.0M |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | Insider | Sell | 29,319 | $191,453 |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | Insider | Sell | 2,400 | $15,312 |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | Insider | Sell | 40,416 | $263,512 |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | Insider | Sell | 32,523 | $204,570 |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 140,057 | $2.5M |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 74,465 | $1.3M |
| 2025-10-10 | Adicet Bio, Inc. (ACET) | Insider | Buy | 1.5M | $0 |
| 2025-10-10 | Adicet Bio, Inc. (ACET) | Insider | Buy | 3.5M | $0 |
| 2025-09-02 | Shattuck Labs, Inc. (STTK) | Director | Buy | 5.3M | $4.6M |
| 2025-09-02 | Shattuck Labs, Inc. (STTK) | Director | Buy | 1.1M | $914,388 |
| 2025-07-30 | ImageneBio, Inc. (IKNA) | Director | Buy | 83,611 | $208,191 |
| 2025-04-11 | Compass Therapeutics, Inc. (CMPX) | Director | Sell | 3.6M | $5.7M |
| 2025-04-04 | Edgewise Therapeutics, Inc. (EWTX) | Director | Buy | 372,578 | $7.5M |
| 2025-04-04 | Edgewise Therapeutics, Inc. (EWTX) | Director | Buy | 124,193 | $2.5M |
| 2025-03-26 | Disc Medicine, Inc. (IRON) | Director | Sell | 1,956 | $105,839 |
Source: SEC Form 4 filings · as of 2026-06-24